Company profile: Elevation Oncology
1.1 - Company Overview
Company description
- Provider of precision medicines as a clinical-stage biopharmaceutical company, developing EO-3021, an antibody-drug conjugate targeting Claudin 18.2 for advanced/metastatic solid tumors, particularly gastric and gastroesophageal junction adenocarcinoma, and Seribantumab, an anti-HER3 monoclonal antibody for NRG1 fusion-positive tumors; conducts clinical trials and offers compassionate use.
Products and services
- Clinical Trials: Clinical-stage program assessing safety and efficacy of investigational therapies EO-3021 and Seribantumab for advanced or metastatic solid tumors
- EO-3021: Investigational antibody-drug conjugate targeting Claudin 18.2, built to treat advanced/metastatic solid tumors expressing CLDN18.2, particularly gastric and gastroesophageal junction adenocarcinoma
- Seribantumab: Investigational anti-HER3 monoclonal antibody evaluated for efficacy in treating advanced or metastatic solid tumors harboring NRG1 fusions
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Elevation Oncology
SmartHealth Dx
HQ: United States
Website
- Description: Provider of precision diagnostics addressing unmet clinical needs in vascular, metabolic, and oncological diseases, including SmartVascular Dx (blood test for vascular inflammation and stroke risk), SmartLung Dx (noninvasive test to identify benign lung nodules), SmartKidney Dx (metastasis risk in kidney disease), SmartScience Dx (~195,000-sample serum repository for biomarker discovery), and SmartPath Dx (real-time pathology imaging).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SmartHealth Dx company profile →
Neon Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies focused on neoantigen-targeted approaches to direct the immune system to recognize and attack cancer. Pipeline includes NEO-PV-01, NEO-PTC-01, and NEO-SV-01.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neon Therapeutics company profile →
HistoGeneX
HQ: Belgium
Website
- Description: Provider of biomarker technologies for translational and clinical research via CAP, CLIA, and BELAC-accredited laboratories. Offers integrated sample management and logistics, biomarker strategy support, oncology assays; flow cytometry, histopathology, genomics, immunoassays; plus CellEngine cytometry analysis software and Olink PEA protein biomarker quantification.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full HistoGeneX company profile →
Aegera Therapeutics
HQ: Canada
Website
- Description: Provider of clinical-stage targeted therapeutics addressing major unmet medical needs, with three programs in clinical development—two in oncology and one in neuropathic pain—and ongoing identification of novel development candidates based on core technologies. Part of Pharmascience Inc.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aegera Therapeutics company profile →
Delcath Systems
HQ: United States
Website
- Description: Provider of interventional oncology therapies for metastatic liver cancer, including HEPZATO KIT for adult patients with metastatic uveal melanoma using a hepatic delivery system; the CHEMOSAT Hepatic Delivery System for melphalan for percutaneous hepatic perfusion to treat liver cancers; and Percutaneous Hepatic Perfusion, a minimally invasive procedure delivering high-dose chemotherapy directly to the liver while isolating the organ from the body’s circulatory system.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Delcath Systems company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Elevation Oncology
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Elevation Oncology
2.2 - Growth funds investing in similar companies to Elevation Oncology
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Elevation Oncology
4.2 - Public trading comparable groups for Elevation Oncology
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →